Teamwork Financial Advisors LLC Sells 734 Shares of Amgen Inc. (NASDAQ:AMGN)

Teamwork Financial Advisors LLC decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 20.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,771 shares of the medical research company’s stock after selling 734 shares during the period. Teamwork Financial Advisors LLC’s holdings in Amgen were worth $788,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Diversified Trust Co lifted its position in Amgen by 76.8% in the 4th quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock worth $10,857,000 after buying an additional 16,376 shares during the last quarter. Provence Wealth Management Group grew its stake in shares of Amgen by 11.9% in the fourth quarter. Provence Wealth Management Group now owns 1,445 shares of the medical research company’s stock worth $416,000 after purchasing an additional 154 shares during the last quarter. Kinsale Capital Group Inc. increased its holdings in Amgen by 33.0% during the 4th quarter. Kinsale Capital Group Inc. now owns 11,348 shares of the medical research company’s stock valued at $3,269,000 after purchasing an additional 2,814 shares during the period. Global Wealth Management Investment Advisory Inc. raised its position in Amgen by 2.4% during the 4th quarter. Global Wealth Management Investment Advisory Inc. now owns 4,733 shares of the medical research company’s stock valued at $1,363,000 after purchasing an additional 109 shares during the last quarter. Finally, Traynor Capital Management Inc. lifted its holdings in Amgen by 9.5% in the 4th quarter. Traynor Capital Management Inc. now owns 18,941 shares of the medical research company’s stock worth $5,455,000 after buying an additional 1,650 shares during the period. Institutional investors own 76.50% of the company’s stock.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 2,117 shares of the stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the sale, the senior vice president now directly owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.69% of the company’s stock.

Amgen Stock Down 0.4 %

NASDAQ:AMGN traded down $1.39 on Thursday, reaching $309.38. 1,000,711 shares of the stock traded hands, compared to its average volume of 2,340,821. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96. The company has a market capitalization of $165.96 billion, a price-to-earnings ratio of 44.20, a PEG ratio of 2.81 and a beta of 0.58. Amgen Inc. has a 12 month low of $218.44 and a 12 month high of $329.72. The company’s fifty day simple moving average is $303.81 and its 200 day simple moving average is $292.91.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, beating the consensus estimate of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The company had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.45 billion. During the same quarter last year, the firm earned $3.98 earnings per share. The firm’s quarterly revenue was up 22.0% compared to the same quarter last year. Equities analysts predict that Amgen Inc. will post 19.47 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on AMGN shares. Royal Bank of Canada boosted their target price on Amgen from $328.00 to $332.00 and gave the company an “outperform” rating in a research note on Friday, June 14th. BMO Capital Markets raised their target price on shares of Amgen from $336.00 to $355.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Morgan Stanley boosted their price target on shares of Amgen from $271.00 to $310.00 and gave the company an “equal weight” rating in a research report on Friday, May 3rd. Mizuho raised their price objective on shares of Amgen from $223.00 to $235.00 and gave the stock a “neutral” rating in a report on Thursday, May 9th. Finally, TD Cowen reduced their target price on Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a report on Wednesday, April 17th. Ten research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $307.35.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.